References
- Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
- Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6 Pt 1), 2186–2190 (2004).
- Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J. Urol.166(4), 1296–1299 (2001).
- Herr H, Lee C, Chang S, Lerner S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J. Urol.171(5), 1823–1828; discussion 1827–1828 (2004).
- Scher H, Bahnson R, Cohen S et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park),12(7A), 225–271 (1998).
- Hollenbeck BK, Dunn RL, Ye Z et al. Delays in diagnosis and bladder cancer mortality. Cancer116(22), 5235–5242 (2010).
- Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks. Cancer115(5), 988–996 (2009).
- Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J. Natl Cancer Inst.95(8), 588–597 (2003).
- Madeb R, Golijanin D, Noyes K et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine?. The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer115(12), 2660–2670 (2009).
- Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J. Urol.180(2), 520–524; discussion 524 (2008).
- Chamie K, Saigal CS, Lai J et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer doi:10.1002/cncr.26198 (2011) (Epub ahead of print).
- Chamie K, Saigal CS, Lai J et al. Quality of care in patients with bladder cancer: a case report?. Cancer doi:10.1002/cncr.26402. (2011)(Epub ahead of print).
- David K, Milowsky M, Ritchey J, Carroll P, Nanus D. Low incidence of perioperative chemotherapy for Stage III bladder cancer 1998 to 2003: a report From the National Cancer Data Base. J. Urol.178(2), 451–454 (2007).
- Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J. Urol.185(1), 72–78 (2011).
- Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol.29(3), 252–258 (2011).
- Gore JL, Litwin MS, Lai J et al. Use of radical cystectomy for patients with invasive bladder cancer. J. Natl Cancer Inst.102(11), 802–811 (2010).
- Hedgepeth RC, Zhang Y, Skolarus TA, Hollenbeck BK. Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology77(2), 385–390 (2011).
- Gore JL, Saigal CS, Hanley JM, Schonlau M, Litwin MS. Variations in reconstruction after radical cystectomy. Cancer107(4), 729–737 (2006).
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
- Lotan Y, Kamat AM, Porter MP et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer115(18), 4096–4103 (2009).